Laboratory Medicine ›› 2015, Vol. 30 ›› Issue (7): 684-690.DOI: 10.3969/j.issn.1673-8640.2015.07.005
• Orginal Article • Previous Articles Next Articles
CHEN Guiying, YANG Tao, YING Jun, HE Xiaohua
Received:
2014-09-23
Online:
2015-07-30
Published:
2015-08-28
CLC Number:
CHEN Guiying, YANG Tao, YING Jun, HE Xiaohua. Performance evaluation of seven eGFR equations for the early diagnosis of CKD[J]. Laboratory Medicine, 2015, 30(7): 684-690.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2015.07.005
公式 | 公式来源 | 方程式 | 相关参数说明 |
---|---|---|---|
eGFR1 | CKD-EPI 2009 Cr公式[ | eGFR1=141×Min(Cr/k,1)a×Max(Cr/k,1)-1.209×0.993年龄(女性×1.108) | k=0.9(男性)/0.7(女性) a=-0.411(男性)/-0.329(女性) |
eGFR2 | CKD-EPI 2012 Cys C公式[ | eGFR2=133×Min(Cys C/0.8,1)-0.499×Max(Cys C/0.8,1)-1.328×0.996年龄(女性×0.932) | |
eGFR3 | CKD-EPI 2012 Cys C-Cr联合公式[ | eGFR3=135×Min(Cys C/0.8,1)-0.375×Max(Cys C/0.8,1)-711×Min(Cr/k,1)a×Max(Cr/k,1)-0.601×0.995年龄(女性×0.969) | k=0.9(男性)/0.7(女性) a=-0.207(男性)/-0.248(女性) |
eGFR4 | 中国eGFR协作组 Cys C公式[ | eGFR4=86×Cys C-1.132 | |
eGFR5 | 中国eGFR协作组 Cys C-Cr联合公式[ | eGFR5=169×Cr-0.608×Cys C-0.630×年龄-0.157(女性×0.83) | |
eGFR6 | FQ-eGFR Cys C公式[ | eGFR6=78.64×Cys C-0.964 | |
eGFR7 | FQ-eGFR Cys C-Cr联合公式[ | eGFR5=173.9×Cr-0.184×Cys C-0.725×年龄-0.193(女性×0.89) |
公式 | 公式来源 | 方程式 | 相关参数说明 |
---|---|---|---|
eGFR1 | CKD-EPI 2009 Cr公式[ | eGFR1=141×Min(Cr/k,1)a×Max(Cr/k,1)-1.209×0.993年龄(女性×1.108) | k=0.9(男性)/0.7(女性) a=-0.411(男性)/-0.329(女性) |
eGFR2 | CKD-EPI 2012 Cys C公式[ | eGFR2=133×Min(Cys C/0.8,1)-0.499×Max(Cys C/0.8,1)-1.328×0.996年龄(女性×0.932) | |
eGFR3 | CKD-EPI 2012 Cys C-Cr联合公式[ | eGFR3=135×Min(Cys C/0.8,1)-0.375×Max(Cys C/0.8,1)-711×Min(Cr/k,1)a×Max(Cr/k,1)-0.601×0.995年龄(女性×0.969) | k=0.9(男性)/0.7(女性) a=-0.207(男性)/-0.248(女性) |
eGFR4 | 中国eGFR协作组 Cys C公式[ | eGFR4=86×Cys C-1.132 | |
eGFR5 | 中国eGFR协作组 Cys C-Cr联合公式[ | eGFR5=169×Cr-0.608×Cys C-0.630×年龄-0.157(女性×0.83) | |
eGFR6 | FQ-eGFR Cys C公式[ | eGFR6=78.64×Cys C-0.964 | |
eGFR7 | FQ-eGFR Cys C-Cr联合公式[ | eGFR5=173.9×Cr-0.184×Cys C-0.725×年龄-0.193(女性×0.89) |
项目 | 例数 | 测定结果[M(范围), mL/(min·1.73 m2)] | 偏差[M(95%CI), mL/(min·1.73 m2)] | 一致性 [ρc(95%CI)] | 准确性 (r值) | 精密度 (Cb值) |
---|---|---|---|---|---|---|
mGFR | 283 | 46.9(6.0~127.2) | - | - | - | - |
eGFR1 | 283 | 40.9(2.4~139.1) | 4.7(2.7~6.6) | 0.726 3(0.671 6~0 .773 1) | 0.755 6 | 0.961 3 |
eGFR2 | 283 | 34.9(5.7~121.2)* | 7.8(5.9~9.9) | 0.812 9(0.771 1~0.847 7) | 0.844 9 | 0.962 3 |
eGFR3 | 283 | 36.6(3.9~127.3)* | 5.2(2.4~7.1) | 0.809 3(0.766 9~0.844 7) | 0.832 4 | 0.972 2 |
eGFR4 | 283 | 43.7(8.1~135.3) | 0.9(-1.3~2.1) | 0.832 9(0.796 3~0.865 3) | 0.834 0 | 0.998 7 |
eGFR5 | 283 | 41.3(4.9~155.9) | 2.7(1.2~4.7) | 0.791 0(0.747 7~0.827 6) | 0.818 2 | 0.966 7 |
eGFR6 | 283 | 44.2(10.5~115.7) | 2.1(0.3~3.7) | 0.822 3(0.782 4~0.856 1) | 0.832 6 | 0.988 1 |
eGFR7 | 283 | 45.7(11.8~120.9) | 0.6(-1.4~2.0) | 0.838 0(0.800 2~0.869 2) | 0.841 3 | 0.996 2 |
项目 | 例数 | 测定结果[M(范围), mL/(min·1.73 m2)] | 偏差[M(95%CI), mL/(min·1.73 m2)] | 一致性 [ρc(95%CI)] | 准确性 (r值) | 精密度 (Cb值) |
---|---|---|---|---|---|---|
mGFR | 283 | 46.9(6.0~127.2) | - | - | - | - |
eGFR1 | 283 | 40.9(2.4~139.1) | 4.7(2.7~6.6) | 0.726 3(0.671 6~0 .773 1) | 0.755 6 | 0.961 3 |
eGFR2 | 283 | 34.9(5.7~121.2)* | 7.8(5.9~9.9) | 0.812 9(0.771 1~0.847 7) | 0.844 9 | 0.962 3 |
eGFR3 | 283 | 36.6(3.9~127.3)* | 5.2(2.4~7.1) | 0.809 3(0.766 9~0.844 7) | 0.832 4 | 0.972 2 |
eGFR4 | 283 | 43.7(8.1~135.3) | 0.9(-1.3~2.1) | 0.832 9(0.796 3~0.865 3) | 0.834 0 | 0.998 7 |
eGFR5 | 283 | 41.3(4.9~155.9) | 2.7(1.2~4.7) | 0.791 0(0.747 7~0.827 6) | 0.818 2 | 0.966 7 |
eGFR6 | 283 | 44.2(10.5~115.7) | 2.1(0.3~3.7) | 0.822 3(0.782 4~0.856 1) | 0.832 6 | 0.988 1 |
eGFR7 | 283 | 45.7(11.8~120.9) | 0.6(-1.4~2.0) | 0.838 0(0.800 2~0.869 2) | 0.841 3 | 0.996 2 |
组别 | mGFR | 例数 | eGFR1 | eGFR2 | eGFR3 | eGFR4 |
---|---|---|---|---|---|---|
A组 | <60 | 189 | 5.5(3.2 ~ 7.7)* | 7.3(4.6 ~ 9,7)* | 5.8(3.8 ~ 8.0)* | -0.2(-2.6 ~ 1.7)# |
B组 | 60~<90 | 65 | 2.6(-9.3 ~ 6.7) | 8.6(5.1 ~ 13.0)*,# | 2.2(-2.4 ~ 6.6) | 0.3(-3.9 ~ 3.3) |
C组 | ≥90 | 29 | 1.3(-17.3 ~ 14.2) | 13.5(4.7 ~ 23.0)# | 0.4(-6.4 ~ 15.2) | 6.3(-0.5 ~ 15.7) |
组别 | mGFR | 例数 | eGFR5 | eGFR6 | eGFR7 | |
A组 | <60 | 189 | 4.7(1.9 ~ 6.6)* | -1.0(-2.9 ~ 0.4)# | -1.7(-4.3 ~ 0.0)# | |
B组 | 60~<90 | 65 | -1.7(-6.1 ~ 3.4) | 5.2(1.4 ~ 9.5) | 3.3(0.1 ~ 6.4) | |
C组 | ≥90 | 29 | -6.0(-20.4 ~ 6.0) | 17.3(11.6 ~ 26.1)*,# | 15.3(6.0 ~ 21.6)* |
组别 | mGFR | 例数 | eGFR1 | eGFR2 | eGFR3 | eGFR4 |
---|---|---|---|---|---|---|
A组 | <60 | 189 | 5.5(3.2 ~ 7.7)* | 7.3(4.6 ~ 9,7)* | 5.8(3.8 ~ 8.0)* | -0.2(-2.6 ~ 1.7)# |
B组 | 60~<90 | 65 | 2.6(-9.3 ~ 6.7) | 8.6(5.1 ~ 13.0)*,# | 2.2(-2.4 ~ 6.6) | 0.3(-3.9 ~ 3.3) |
C组 | ≥90 | 29 | 1.3(-17.3 ~ 14.2) | 13.5(4.7 ~ 23.0)# | 0.4(-6.4 ~ 15.2) | 6.3(-0.5 ~ 15.7) |
组别 | mGFR | 例数 | eGFR5 | eGFR6 | eGFR7 | |
A组 | <60 | 189 | 4.7(1.9 ~ 6.6)* | -1.0(-2.9 ~ 0.4)# | -1.7(-4.3 ~ 0.0)# | |
B组 | 60~<90 | 65 | -1.7(-6.1 ~ 3.4) | 5.2(1.4 ~ 9.5) | 3.3(0.1 ~ 6.4) | |
C组 | ≥90 | 29 | -6.0(-20.4 ~ 6.0) | 17.3(11.6 ~ 26.1)*,# | 15.3(6.0 ~ 21.6)* |
组别 | mGFR | 例数 | eGFR1 | eGFR2 | eGFR3 | eGFR4 |
---|---|---|---|---|---|---|
A组 | <60 | 189 | 11.4(10.1 ~ 12.9)* | 8.9(7.3 ~ 9.4)# | 8.6(6.2 ~ 10.4)# | 8.5(7.1 ~ 9.7)# |
B组 | 60~<90 | 65 | 18.9(16.1 ~ 20.0)* | 9.7(4.9 ~ 12.2)# | 9.7(4.9 ~ 14.2)# | 8.0(1.4 ~ 12.0)# |
C组 | ≥90 | 29 | 20.7(16.6 ~ 29.4)* | 12.0(7.1 ~ 16.4)# | 16.3(11.6 ~ 20.1) | 12.7(4.8 ~ 15.9)# |
组别 | mGFR | 例数 | eGFR5 | eGFR6 | eGFR7 | |
A组 | <60 | 189 | 8.7(7.1 ~ 10.7)# | 8.2(6.9 ~ 9.5)# | 8.3(6.8 ~ 9.4)# | |
B组 | 60~<90 | 65 | 12.7(6.0 ~ 14.0)*,# | 7.7(3.6 ~ 9.7)# | 8.9(7.8 ~ 10.4)# | |
C组 | ≥90 | 29 | 20.7(15.1 ~ 24.6)* | 11.0(5.8 ~ 13.4)# | 11.9(5.8 ~ 13.9)# |
组别 | mGFR | 例数 | eGFR1 | eGFR2 | eGFR3 | eGFR4 |
---|---|---|---|---|---|---|
A组 | <60 | 189 | 11.4(10.1 ~ 12.9)* | 8.9(7.3 ~ 9.4)# | 8.6(6.2 ~ 10.4)# | 8.5(7.1 ~ 9.7)# |
B组 | 60~<90 | 65 | 18.9(16.1 ~ 20.0)* | 9.7(4.9 ~ 12.2)# | 9.7(4.9 ~ 14.2)# | 8.0(1.4 ~ 12.0)# |
C组 | ≥90 | 29 | 20.7(16.6 ~ 29.4)* | 12.0(7.1 ~ 16.4)# | 16.3(11.6 ~ 20.1) | 12.7(4.8 ~ 15.9)# |
组别 | mGFR | 例数 | eGFR5 | eGFR6 | eGFR7 | |
A组 | <60 | 189 | 8.7(7.1 ~ 10.7)# | 8.2(6.9 ~ 9.5)# | 8.3(6.8 ~ 9.4)# | |
B组 | 60~<90 | 65 | 12.7(6.0 ~ 14.0)*,# | 7.7(3.6 ~ 9.7)# | 8.9(7.8 ~ 10.4)# | |
C组 | ≥90 | 29 | 20.7(15.1 ~ 24.6)* | 11.0(5.8 ~ 13.4)# | 11.9(5.8 ~ 13.9)# |
组别 | mGFR | 例数 | eGFR1 | eGFR2 | eGFR3 | eGFR4 |
---|---|---|---|---|---|---|
A组 | <60 | 189 | 44.4(35.5 ~ 55.0)* | 42.9(34.0 ~ 53.3)* | 43.9(35.0 ~ 54.4)* | 29.6(22.4 ~ 38.5)# |
B组 | 60~<90 | 65 | 38.5(24.9 ~ 56.8)* | 26.2(15.2 ~ 41.9) | 24.6(14.1 ~ 40.0) | 24.6(14.1 ~ 40.0) |
C组 | ≥90 | 29 | 27.6(11.9 ~ 54.4)* | 6.9(0.8 ~ 24.9) | 6.9(0.8 ~ 24.9) | 13.8(3.8 ~ 35.3) |
组别 | mGFR | 例数 | eGFR5 | eGFR6 | eGFR7 | |
A组 | <60 | 189 | 35.5(27.5 ~ 45.0)* | 27.5(20.6 ~ 36.1)# | 23.8(17.4 ~ 31.9)# | |
B组 | 60~<90 | 65 | 26.2(15.2 ~ 41.9) | 18.5(9.5 ~ 32.3)# | 13.8(6.3 ~ 26.3)# | |
C组 | ≥90 | 29 | 20.7(7.6 ~ 45.0) | 20.7(7.6 ~ 45.0) | 3.4(0.0 ~ 19.2)# |
组别 | mGFR | 例数 | eGFR1 | eGFR2 | eGFR3 | eGFR4 |
---|---|---|---|---|---|---|
A组 | <60 | 189 | 44.4(35.5 ~ 55.0)* | 42.9(34.0 ~ 53.3)* | 43.9(35.0 ~ 54.4)* | 29.6(22.4 ~ 38.5)# |
B组 | 60~<90 | 65 | 38.5(24.9 ~ 56.8)* | 26.2(15.2 ~ 41.9) | 24.6(14.1 ~ 40.0) | 24.6(14.1 ~ 40.0) |
C组 | ≥90 | 29 | 27.6(11.9 ~ 54.4)* | 6.9(0.8 ~ 24.9) | 6.9(0.8 ~ 24.9) | 13.8(3.8 ~ 35.3) |
组别 | mGFR | 例数 | eGFR5 | eGFR6 | eGFR7 | |
A组 | <60 | 189 | 35.5(27.5 ~ 45.0)* | 27.5(20.6 ~ 36.1)# | 23.8(17.4 ~ 31.9)# | |
B组 | 60~<90 | 65 | 26.2(15.2 ~ 41.9) | 18.5(9.5 ~ 32.3)# | 13.8(6.3 ~ 26.3)# | |
C组 | ≥90 | 29 | 20.7(7.6 ~ 45.0) | 20.7(7.6 ~ 45.0) | 3.4(0.0 ~ 19.2)# |
项目 | eGFR1 | eGFR2 | eGFR3 | eGFR4 | eGFR5 | eGFR6 | eGFR7 |
---|---|---|---|---|---|---|---|
CKD发生率(%) | 9.6 | 16.3 | 10.7 | 11.6 | 9.5 | 12.6 | 11.0 |
95%CI | 9.0~10.3 | 15.5~17.1 | 10.0~11.4 | 10.9~12.3 | 8.9~10.2 | 11.9~13.4 | 10.3~11.7 |
IRR(P值)* | - | 1.69(0.000) | 1.11(0.026) | 1.20(0.000) | 0.99(0.831) | 1.31(0.000) | 1.14(0.005) |
项目 | eGFR1 | eGFR2 | eGFR3 | eGFR4 | eGFR5 | eGFR6 | eGFR7 |
---|---|---|---|---|---|---|---|
CKD发生率(%) | 9.6 | 16.3 | 10.7 | 11.6 | 9.5 | 12.6 | 11.0 |
95%CI | 9.0~10.3 | 15.5~17.1 | 10.0~11.4 | 10.9~12.3 | 8.9~10.2 | 11.9~13.4 | 10.3~11.7 |
IRR(P值)* | - | 1.69(0.000) | 1.11(0.026) | 1.20(0.000) | 0.99(0.831) | 1.31(0.000) | 1.14(0.005) |
年龄(岁) | 例数 | eGFR1 | eGFR2 | eGFR3 | eGFR4 |
---|---|---|---|---|---|
≤65 | 8 120 | 7.1(6.6~7.7) | 11.7(11.0~12.5) | 7.6(7.0~8.3) | 8.9(8.3~9.6) |
>65 | 1 187 | 26.9(24.0~30.0) | 47.7(43.8~51.8) | 31.5(28.4~34.9) | 29.8(26.8~33.1) |
IRR(P值)* | 3.77(0.000) | 4.07(0.000) | 4.13(0.000) | 3.34(0.000) | |
年龄(岁) | 例数 | eGFR5 | eGFR6 | eGFR7 | |
≤65 | 8 120 | 7.2(6.6~7.8) | 9.8(9.2~10.5) | 7.8(7.2~8.4) | |
>65 | 1 187 | 25.8(23.0~28.8) | 31.6(28.5~35.0) | 32.7(29.5~36.1) | |
IRR(P值)* | 3.60(0.000) | 3.21(0.000) | 4.18(0.000) |
年龄(岁) | 例数 | eGFR1 | eGFR2 | eGFR3 | eGFR4 |
---|---|---|---|---|---|
≤65 | 8 120 | 7.1(6.6~7.7) | 11.7(11.0~12.5) | 7.6(7.0~8.3) | 8.9(8.3~9.6) |
>65 | 1 187 | 26.9(24.0~30.0) | 47.7(43.8~51.8) | 31.5(28.4~34.9) | 29.8(26.8~33.1) |
IRR(P值)* | 3.77(0.000) | 4.07(0.000) | 4.13(0.000) | 3.34(0.000) | |
年龄(岁) | 例数 | eGFR5 | eGFR6 | eGFR7 | |
≤65 | 8 120 | 7.2(6.6~7.8) | 9.8(9.2~10.5) | 7.8(7.2~8.4) | |
>65 | 1 187 | 25.8(23.0~28.8) | 31.6(28.5~35.0) | 32.7(29.5~36.1) | |
IRR(P值)* | 3.60(0.000) | 3.21(0.000) | 4.18(0.000) |
[1] | MYERS GL,MILLER WG,CORESH J,et al.Recom-mendations for improving serum creatinine measurement: a report from the laboratory working group of the National Kidney Disease Education Program[J]. Clin Chem,2006,52(1):5-18. |
[2] | LARSSON A,FLODIN M,HANSSON LO,et al.Patient selection has a strong impact on cystatin C and modification of diet in renal disease (MDRD) estimated glomerular filtration rate[J]. Clin Biochem,2008,41(16-17):1355-1361. |
[3] | Kidney Disease:Improving Global Outcomes(KIDGO) CKD Work Group. KIDGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J/OL]. Kidney Inter,2013,3(1):1-150.[2013-01-03].. |
[4] | ZHANG M,CHEN Y,TANG L,et al.Applicability of chronic kidney disease epidemiology collaboration equations in a Chinese population[J]. Nephrol Dial Transplant,2014,29(3):580-586. |
[5] | INKER LA,SCHMID CH,TIGHIOUART H,et al.Estimating glomerular filtration rate from serum creatinine and cystatin C[J]. N Engl J Med,2012,367(1):20-29. |
[6] | MA YC,ZUO L,CHEN JH,et al.Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease[J]. J Am Soc Nephrol,2006,17(10):2937-2944. |
[7] | FENG JF,QIU L,ZHANG L,et al.Multicenter study of creatinine- and/or cystatin C-based equations for estimation of glomerular filtration rates in Chinese patients with chronic kidney disease[J]. PLoS One,2013,8(3):e57240. |
[8] | ZUO L,YING-CHUN,WANG M,et al.Prediction of two-sample (99m)Tc-diethylene triamine pentaacetic acid plasma clearance from single-sample method[J]. Ann Nucl Med,2005,19(5):399-405. |
[9] | LIN LI.A concordance correlation coefficient to evaluate reproducibility[J]. Biometrics,1989,45(1):255-268. |
[10] | ZHANG L,WANG F,WANG L,et al.Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet,2012,379(9818):815-822. |
[11] | 徐晓萍,徐磊,朱清,等. 临床实践中慢性肾功能损伤早期的实验室预警指标分析[J]. 检验医学,2010,25(4):257-261. |
[12] | ZHU Y,YE X,ZHU B,et al.Comparisons between the 2012 new CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations and other four approved equations[J]. PLoS One,2014,9(1):e84688. |
[13] | 贾珂珂,杨硕,乔蕊,等. 6种基于血肌酐的肾小球滤过率估算公式在健康人群中的应用评估[J]. 检验医学,2013,28(12):1077-1082. |
[14] | 陆汉魁. 应用放射性核素方法测量肾小球滤过率及相关技术问题[J]. 中华检验医学杂志,2007,30(11):1211-1212. |
[15] | 马清光,李慧敏,沈丽. 血清半胱氨酸蛋白酶抑制剂C、肌酐评估慢性肾病患者肾小球滤过功能价值的Meta分析[J]. 检验医学,2012,27(5):352-357. |
[16] | OH SW,KIM S,NA KY,et al.Glomerular filtration rate and proteinuria: association with mortality and renal progression in a prospective cohort of a community-based elderly population[J]. PLoS One,2014,9(4):e94120. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||